Biornarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs

被引：134
|
作者：
Wagner, J. A. [1 ]
Williams, S. A.
Webster, C. J.
机构：
[1] Merck & Co Inc, Rahway, NJ 07065 USA
[2] Pfizer Global Res & Dev, New London, CT USA
[3] Millennium Pharmaceut Inc, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 81卷 / 01期
关键词：
D O I：
10.1038/sj.clpt.6100017
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
A consistent framework for the acceptance and qualification of biomarkers for regulatory use is needed to facilitate innovative and efficient research and subsequent application of biomarkers in drug development. One key activity is biomarker qualification, a graded, "fit-for-purpose" evidentiary process linking a biomarker with biology and clinical end points. A biomarker consortium model win distribute cost and risk, and drive efficient execution of research and ultimately regulatory acceptance of biomarkers for specific indications.
引用
收藏
页码：104 / 107
页数：4
相关论文
共 50 条
  • [1] Commentary on Fit-For-Purpose Models for Regulatory Applications
    Wang, Yaning
    Huang, Shiew Mei
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (01) : 18 - 20
  • [2] Therapeutic monitoring of psychoactive drugs: are measurements fit-for-purpose?
    Wilson, J. F.
    [J]. THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 525 - 525
  • [3] Nanofiltration for circularity: Fit-for-purpose design and evaluation
    Villalobos, Luis Francisco
    Zhang, Junwei
    Elimelech, Menachem
    [J]. ONE EARTH, 2023, 6 (07): : 767 - 771
  • [4] Fit-for-purpose Land Administration for Sustainable Development
    Enemark, Stig
    [J]. GIM INTERNATIONAL-THE WORLDWIDE MAGAZINE FOR GEOMATICS, 2016, 30 (08): : 16 - 19
  • [5] Strategic approach to fit-for-purpose biomarkers in drug development
    Wagner, John A.
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2008, 48 : 631 - 651
  • [6] DEVELOPMENT OF A FIT-FOR-PURPOSE TOBACCO AND NICOTINE PRODUCTS DEPENDENCE INSTRUMENT
    Chrea, C.
    Salzberger, T.
    Abetz-Webb, L.
    Afolalu, E. F.
    Cano, S.
    Rose, J.
    Weitkunat, R.
    Fagerstrom, K.
    [J]. VALUE IN HEALTH, 2018, 21 : S387 - S387
  • [7] Fit-for-purpose biomarker method validation in anticancer drug development
    Cummings, Jeffrey
    Ward, Tim H.
    Dive, Caroline
    [J]. DRUG DISCOVERY TODAY, 2010, 15 (19-20) : 816 - 825
  • [8] The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development
    Lathia, C. D.
    Amakye, D.
    Dai, W.
    Girman, C.
    Madani, S.
    Mayne, J.
    MacCarthy, P.
    Pertel, P.
    Seman, L.
    Stoch, A.
    Tarantino, P.
    Webster, C.
    Williams, S.
    Wagner, J. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (01) : 32 - 43
  • [9] A framework for a fit-for-purpose evaluation of non-animal methods
    Boobis, A. R.
    [J]. TOXICOLOGY LETTERS, 2018, 295 : S17 - S17
  • [10] Fit-for-purpose method development and validation for successful biomarker measurement
    Lee, JW
    Devanarayan, V
    Barrett, YC
    Weiner, R
    Allinson, J
    Fountain, S
    Keller, S
    Weinryb, I
    Green, M
    Duan, L
    Rogers, JA
    Millham, R
    O'Brien, PJ
    Sailstad, J
    Khan, M
    Ray, C
    Wagner, JA
    [J]. PHARMACEUTICAL RESEARCH, 2006, 23 (02) : 312 - 328
12345